Research programme: bispecific anticancer antibodies - Schering/IBC PharmaceuticalsAlternative Names: Bispecific anticancer antibodies - Schering/IBC Pharmaceuticals
Latest Information Update: 24 Mar 2010
At a glance
- Originator Bayer Schering Pharma; IBC Pharmaceuticals
- Class Antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Oct 2003 Preclinical trials in Cancer in USA (unspecified route)